FineMark National Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

FineMark National Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-428	Closed	-$208K	–	469
2025 Q1	$208K	Buy	+428	New	+$199K	0.01%	414
2024 Q3	–	Sell	-428	Closed	-$201K	–	437
2024 Q2	$201K	Sell	428 -388	-48%	-$168K	0.01%	407
2024 Q1	$341K	Buy	+816	New	+$345K	0.01%	334
2023 Q3	–	Sell	-845	Closed	-$297K	–	439
2023 Q2	$297K	Buy	+845	New	+$285K	0.01%	348
2017 Q1	–	Sell	-300	Closed	-$22K	–	989
2016 Q4	$22K	Hold	300	–	–	﹤0.01%	807
2016 Q3	$26K	Sell	300 -15	-5%	-$1.42K	﹤0.01%	759
2016 Q2	$27K	Buy	315 +15	+5%	+$1.3K	﹤0.01%	764
2016 Q1	$24K	Hold	300	–	–	﹤0.01%	752
2015 Q4	$38K	Sell	300 -20	-6%	-$2.41K	﹤0.01%	665
2015 Q3	$33K	Buy	320 +20	+7%	+$2.57K	﹤0.01%	743
2015 Q2	$37K	Sell	300 -200	-40%	-$25.2K	﹤0.01%	737
2015 Q1	$59K	Buy	500 +200	+67%	+$24K	0.01%	623
2014 Q4	$36K	Hold	300	–	–	0.01%	762
2014 Q3	$34K	Hold	300	–	–	0.01%	744
2014 Q2	$28K	Hold	300	–	–	﹤0.01%	807
2014 Q1	$21K	Hold	300	–	–	﹤0.01%	878
2013 Q4	$22K	Hold	300	–	–	﹤0.01%	810
2013 Q3	$23K	Sell	300 -104	-26%	-$8.28K	0.01%	761
2013 Q2	$32K	Buy	+404	New	+$29.8K	0.01%	660

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FineMark National Bank & Trust's VRTX Position: Q2 2025 in Review

FineMark National Bank & Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 428 shares — an estimated $208K sold.

FineMark National Bank & Trust first reported a position in VRTX in Q2 2013 and held it in 19 quarters. The position peaked at $341K in Q1 2024. 1,560 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

FineMark National Bank & Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
FineMark National Bank & Trust sold 428 Vertex Pharmaceuticals shares in Q2 2025, an estimated $208K.
FineMark National Bank & Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 19 quarters.
FineMark National Bank & Trust's Vertex Pharmaceuticals position peaked at $341K in Q1 2024.
1,560 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on FineMark National Bank & Trust's 13F filing for Q2 2025, filed 11 Aug 2025.